FibroBiologics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
455 E. MEDICAL CENTER BLVD, HOUSTON, TX, 77598
Mailing Address
455 E. MEDICAL CENTER BLVD SUITE 300, HOUSTON, TX, 77598
Phone
281-671-5150
Fiscal Year End
1231
EIN
863329066
Financial Overview
FY2025
-$11.16M
Net Income
$13.71M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-1 IPO registration statement | March 27, 2026 | View on SEC |
| 10-K/A Annual report amendment | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 10-K Annual financial report | February 24, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
Material Events
8-K
Financial Distress
February 23, 2026
High Impact
- Shareholders approved a reverse stock split to maintain Nasdaq listing and avoid delisting.
- Approved the issuance of up to 22.3 million new shares for warrant exercises, securing future capital for operations and R&D.
8-K
Financial Distress
February 6, 2026
High Impact
- FibroBiologics faces dual Nasdaq non-compliance for failing to maintain a minimum share price ($1.00) and market value ($35 million).
- The company has proposed a reverse stock split (ranging from 1-for-5 to 1-for-30 shares) to regain compliance with Nasdaq rules.
8-K
Financial Distress
January 2, 2026
High Impact
- FibroBiologics received a serious warning that its shares might be removed from the Nasdaq stock exchange due to its stock price being too low for too long.
- The company's stock price has consistently traded below $1.00 per share, violating Nasdaq's minimum bid price rule.
Insider Trading
BUY
4 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN
Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB
Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT
Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA
Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN
Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.